Our Grants

CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.

See our complete portfolio of awards below.

View Funded Institutions
View Funded Investigators
Find Clinical Trials

All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
University of California, Los Angeles Dr. Stanley Nelson Early Translational from Disease Team Conversion Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy $1,823,545
University of California, Los Angeles Dr. Robert Reiter MD Early Translational IV Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells $4,075,668
Human BioMolecular Research Institute Dr. John R Cashman Ph.D. Early Translational IV Improving Existing Drugs for Long QT Syndrome type 3 (LQT3) by hiPSC Disease-in-Dish Model $6,361,369
Numerate, Inc. Dr. John H Griffin Early Translational IV Use of human iPSC-derived neurons from Huntington’s Disease patients to develop novel, disease-modifying small molecule structural corrector drug candidates targeting the unique, neurotoxic conformation of mutant huntingtin $520,015
University of California, Los Angeles Dr. Jerome A. Zack Ph.D. Early Translational IV Stem Cell Programming With Chimeric Antigen Receptors to Eradicate HIV Infection $4,925,166
University of California, Los Angeles Dr. Gerald Lipshutz Early Translational IV Gene therapy-corrected autologous hepatocyte-like cells from induced pluripotent stem cells for the treatment of pediatric single enzyme disorders $1,801,629
University of California, Los Angeles Dr. Donald B. Kohn Early Translational IV Beta-Globin Gene Correction of Sickle Cell Disease in Hematopoietic Stem Cells $1,651,884
Salk Institute for Biological Studies Dr. Inder M. Verma Early Translational IV Development of a cell and gene based therapy for hemophilia $2,298,634
The Scintillon Institute Dr. Stuart A Lipton Early Translational IV Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke $1,103,185
Sanford Burnham Prebys Medical Discovery Institute Dr. Stuart A Lipton Early Translational IV Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke $1,020,815
University of California, San Diego Professor Alysson R Muotri Early Translational IV A drug-screening platform for autism spectrum disorders using human astrocytes $1,656,456
Cedars-Sinai Medical Center Dr. Dan Gazit Early Translational IV Gene Targeting to Endogenous Stem Cells for Segmental Bone Fracture Healing $5,121,514
Stanford University Dr. Michele Calos Early Translational IV Engineered iPSC for therapy of limb girdle muscular dystrophy type 2B $1,876,253
Gladstone Institutes, J. David Dr. Steve M. Finkbeiner Early Translational IV Development of Novel Autophagy Inducers to Block the Progression of and Treat Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Diseases $2,049,053
University of California, Irvine Dr. Magdalene J Seiler Early Translational IV Restoring vision by sheet transplants of retinal progenitors and retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs) $3,998,948
ViaCyte, Inc. Howard Foyt Strategic Partnership I Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes $9,475,070
Bluebird Bio David M. Davidson Strategic Partnership I A Phase 1/2, Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects with β-Thalassemia by Transplantation of Autologous Hematopoietic Stem Cells Transduced with the Lentiviral Vector LentiGlobin® Encoding the Human β-A-T87Q-… $0
FUJIFILM Cellular Dynamics Inc. Deborah Requesens hPSC Repository The CIRM Human Pluripotent Stem Cell Biorepository – A Resource for Safe Storage and Distribution of High Quality iPSCs $9,942,175
Cellular Dynamics International Dr. Thomas J Novak hiPSC Derivation Generation and characterization of high-quality, footprint-free human induced pluripotent stem cell lines from 3,000 donors to investigate multigenic diseases $16,000,000
University of California, San Diego Dr. Joseph G. Gleeson Tissue Collection for Disease Modeling CIRM Tissue Collection for Neurodevelopmental Disabilities $830,426
University of California, San Diego Dr. Kang Zhang M.D. Tissue Collection for Disease Modeling Generation of fibroblast cell lines in patients with common blinding eye diseases $1,034,425
Stanford University Dr. Joseph C. Wu Tissue Collection for Disease Modeling Tissue Collection for Accelerating iPSC Research in Cardiovascular Diseases $1,291,832
University of California, San Diego Dr. James Brewer Tissue Collection for Disease Modeling Collection of skin biopsies to prepare fibroblasts from patients with Alzheimer’s disease and cognitively healthy elderly controls $643,693
Stanford University Dr. Joachim Franz Hallmayer Tissue Collection for Disease Modeling Induced pluripotent stem cells from children with autism spectrum disorders $530,265
University of California, Los Angeles Dr. Brigitte Gomperts Tissue Collection for Disease Modeling Using human induced pluripotent stem cells to improve our understanding of Idiopathic Pulmonary Fibrosis $811,231
University of California, San Francisco Jacquelyn J Maher Tissue Collection for Disease Modeling iPSC-derived Hepatocytes as Platforms for Research in Viral Hepatitis and Non-alcoholic Steatohepatitis $791,680
Cedars-Sinai Medical Center Professor Clive Niels Svendsen Disease Team Therapy Planning I Stem Cells Secreting GDNF for the Treatment of ALS $63,487
1 … 23 24 25 26 27 28 29 30 31 32 33